OTCMMYZQF
Market cap784kUSD
Oct 31, Last price
0.00USD
Name
Advanced Health Intelligence Ltd
Chart & Performance
P/E
—
P/S
0.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.71%
Rev. gr., 5y
256.68%
Revenues
3m
+309.50%
Net income
-4m
L-67.67%
CFO
-5m
L-35.57%
Earnings
Apr 16, 2025
Profile
Advanced Human Imaging Limited operates as a mobile application and technology development company in Australia and internationally. It develops and patents BodyScan, a proprietary measurement/dimensioning technology that enables end-user to check and assess body dimensions using a smartphone. The company also provides FaceScan for measuring vital signs, and risks associated with cardiovascular disease, heart attack, and stroke; and DermaScan, a dermatological scanner. It serves mobile health and telehealth, life and health insurance, fitness and wellness, and consumer apparel sectors. The company was formerly known as MyFiziq Limited and changed its name to Advanced Human Imaging Limited in March 2021. Advanced Human Imaging Limited was incorporated in 2014 and is based in South Perth, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | 2015‑04 | |
| Income | |||||||||||
Revenues | 2,682 309.50% | 655 154.21% | 258 -56.59% | ||||||||
Cost of revenue | 10,263 | 11,946 | 22,844 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (7,581) | (11,291) | (22,587) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (890) | ||||||||||
Tax Rate | |||||||||||
NOPAT | (7,581) | (11,291) | (21,696) | ||||||||
Net income | (4,147) -67.67% | (12,827) -36.11% | (20,077) 42.78% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 5,000 | 18,233 | |||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | 723 | 1,498 | 1,161 | ||||||||
Long-term debt | 2,026 | 675 | 51 | ||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 700 | 547 | 63 | ||||||||
Net debt | (3,385) | (695) | (7,364) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (4,747) | (7,367) | (7,294) | ||||||||
CAPEX | (2) | (67) | (86) | ||||||||
Cash from investing activities | (96) | (669) | (3,385) | ||||||||
Cash from financing activities | 2,783 | 4,169 | 17,082 | ||||||||
FCF | (944) | (9,891) | (21,741) | ||||||||
| Balance | |||||||||||
Cash | 26 | 2,105 | 6,011 | ||||||||
Long term investments | 6,109 | 764 | 2,565 | ||||||||
Excess cash | 6,000 | 2,836 | 8,564 | ||||||||
Stockholders' equity | 3,280 | 2,028 | 8,555 | ||||||||
Invested Capital | 3,144 | 1,945 | 1,224 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 254,803 | 184,837 | 153,489 | ||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | (7,223) | (10,920) | (22,223) | ||||||||
EV/EBITDA | |||||||||||
Interest | 688 | 478 | 164 | ||||||||
Interest/NOPBT | |||||||||||